research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
Search
for
Sort by
Research
240-270 / 1000+ results 
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Successful Treatment of Alopecia Totalis with Topical Calcipotriol: Serial Case Report and Review of the Literature
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
research The efficacy and safety of tofacitinib in patients with alopecia totalis
Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
research Skin image analysis for detection and quantitative assessment of dermatitis, vitiligo and alopecia areata lesions: a systematic literature review
Computer vision techniques can help detect and assess skin conditions like vitiligo, alopecia areata, and dermatitis.
research Alopecia Areata in Children: Quality of Life for Children and Their Parents
Alopecia areata severity and child's age greatly affect the quality of life for children and their parents.
research The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.
research Management of Pediatric Alopecia Universalis through Ayurveda: An experience
Ayurvedic treatment significantly improved hair regrowth in a child with Alopecia Universalis.
research An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
research The study of premature canities and its association in tertiary care hospital
Premature graying of hair is often linked with other health issues, but treatment with biotin, zinc, and calcium pantothenate is not very effective.
research Etiopathogenesis of Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
research Status of Serum Vitamin-D Level among the Patients with Alopecia Areata in a Tertiary Care Hospital, Bangladesh
People with alopecia areata have much lower Vitamin-D levels than healthy individuals.
research Severity Prediction of Hair Loss in Alopecia Areata with Hybrid Deep Learning Architecture
The model accurately predicts hair loss severity in alopecia areata.
research Comparison of Trichoscopic Features of Alopecia Areata before and after Treatment with Intralesional Steroids
Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
research A randomised, open label comparative study of hydroxychloroquine with betamethasone oral mini pulse in the management of patients with alopecia areata
Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Serum level of calprotectin as a new inflammatory marker in patients with alopacia areata
Calprotectin levels are higher in alopecia areata patients, indicating systemic inflammation.
research Assessment of Vitamin D Level in Patients of Alopecia Areata
Low vitamin D levels are common in people with Alopecia Areata.
research Hearing impairment in patients with alopecia areata
Alopecia areata may lead to hearing loss.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
research Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study
Hypothyroidism is often linked to the hair loss condition telogen effluvium.
research II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.